|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Y Shabo and L Sachs
Department of Genetics, Weizmann Institute of Science, Rehovot, Israel.
The normal myeloid hematopoietic regulatory proteins include four
growth-inducing proteins called colony-stimulating factors (CSF), including
interleukin-3 (IL-3), or macrophage and granulocyte inducers, type 1
(MGI-1), and another type of protein (MGI-2) with no myeloid cell
growth-inducing activity that induces differentiation of normal myeloid
precursor cells and certain clones of myeloid leukemic cells. An IgG2a
monoclonal antibody was prepared and it neutralized two forms of MGI-2
(MGI-2A and MGI-2B) produced by mouse Krebs ascites tumor cells. The
monoclonal antibody was used for affinity purification of MGI-2. This
antibody also neutralized MGI-2 produced by normal mouse macrophages,
normal myeloblasts incubated with IL-3, and MGI-2 produced by the lungs and
found in the serum of mice injected with lipopolysaccharide (LPS). The
anti-MGI-2 antibody did not inhibit the activity of any one of the four
myeloid growth-inducing proteins (CSF or IL-3 = MGI-1), IL-1, tumor
necrosis factor, or lymphotoxin. This antibody also inhibited induction of
differentiation of myeloid leukemic cells by LPS, which is mediated by the
endogenous production of MGI-2, but did not inhibit induction of
differentiation in these leukemic cells by dexamethasone or cytosine
arabinoside, which is not mediated by MGI-2. Anti-MGI-2 antibody thus
inhibited differentiation when MGI-2 was added externally to cells or when
it was mediated by endogenously produced MGI-2.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1988 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
